1,124 results on '"Pigneux, Arnaud"'
Search Results
2. Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study
3. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.
4. Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study
5. Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy
6. Faire vivre et grandir une communauté de chefs de service : acte 2 en hématologie
7. Low frequency of Vγ9Vδ2 T cells predicts poor survival in newly diagnosed acute myeloid leukemia
8. Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial
9. Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS
10. Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia
11. Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study
12. Cost comparison of post-remission strategies in younger and older AML patients in France
13. Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO
14. Overlapping features of therapy-related and de novo NPM1-mutated AML
15. Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial
16. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial
17. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial
18. Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study
19. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial
20. Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries
21. In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study
22. Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia.
23. Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML
24. Mini-consolidations or intermediate-dose cytarabine (IDAC) for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries.
25. Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study.
26. Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML
27. Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant
28. Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia
29. A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries
30. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study
31. Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT
32. A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia
33. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort
34. Antifungal Stewardship in Hematology: Reflection of a Multidisciplinary Group of Experts
35. First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC.
36. Horizontal meta-analysis identifies common deregulated genes across AML subgroups providing a robust prognostic signature
37. Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome
38. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.
39. Phase II, multicenter, randomized trial of CPX‐351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML
40. Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
41. An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes
42. Clonal Dynamics of FLT3-ITD Positive Acute Myeloid Leukemia Patients with Relapsed/Refractory Disease Following Intensive Chemotherapy +/- Midostaurin
43. Long-Term Real-World Experience of CPX-351 in Combined French-Italian Cohorts Identified High Rate of Negative Measurable Residual Disease (MRD) and Prolonged Overall Survival
44. CO3-3 Impact de la diminution du seuil transfusionnel en hématologie
45. AML-108 SELECT-AML-1 Trial in Progress: A Phase 2 Study of Tamibarotene in Combination With Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-Positive AML who are Ineligible for Standard Induction Therapy
46. Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression
47. PB1773: AML AND MDS WITH RARA OVEREXPRESSION: MOLECULAR AND CLINICAL FEATURES OF PATIENTS ENROLLED IN A PHASE 2 TRIAL EVALUATING TAMIBAROTENE-BASED THERAPY
48. P537: SAFETY AND TOLERABILITY OF AZD0466 AS MONOTHERAPY FOR PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES - PRELIMINARY RESULTS FROM AN ONGOING PHASE I/II TRIAL
49. Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA
50. Prognostic value of postinduction medullary myeloid recovery by flow cytometry in acute myeloid leukemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.